Labcorp Announces FDA Approval of Companion Diagnostic Supporting Patients with Advanced Melanoma

Rhea-AI Summary

Labcorp (NYSE: LH) announced that the U.S. Food and Drug Administration has approved its PGDx elio® tissue complete CDx as a companion diagnostic for patients with advanced melanoma.

The test helps identify patients whose tumors harbor specific BRAF V600E/K variants, indicating they may benefit from FDA‑approved BRAF inhibitor and BRAF/MEK inhibitor combination therapies. According to Labcorp, melanoma is the deadliest form of skin cancer, and targeted therapies are an important option for stage IV patients with BRAF alterations. The kit‑based CDx can be used by qualified healthcare professionals across hospitals and clinical laboratories, enabling institutions to implement testing on‑site, retain samples and data, and potentially support future clinical research. This approval also expands Labcorp’s precision medicine portfolio of tissue‑ and liquid‑based oncology diagnostics designed to support personalized care.

Positive

• FDA approval of PGDx elio tissue complete CDx as a companion diagnostic for advanced melanoma
• Test identifies BRAF V600E/K variants to guide use of FDA‑approved targeted therapies
• Kit‑based CDx deployable across hospitals and clinical labs, broadening access to molecular testing
• Approval expands Labcorp’s precision medicine oncology diagnostics portfolio

Negative

• None.

Market Context

The single tag-specific precedent, news_id 760225, recorded a 0% 24-hour move. It adds historical co...

Analysis

The single tag-specific precedent, news_id 760225, recorded a 0% 24-hour move. It adds historical context to this FDA approval, while recent insider data showed Net Selling; execution and adoption remain points to watch.

Key Figures

Stage IV five-year survival rate: 16%

1 metrics

Stage IV five-year survival rate 16% Patients diagnosed with stage IV melanoma

Previous Fda approval Reports

1 past event · Latest: Oct 16 (Positive)

Same Type Pattern 1 events

Date	Event	Sentiment	24h Move	Catalyst
Oct 16	FDA collaboration	Positive	+0.0%	FDA-authorized syphilis test collaboration expanded Labcorp distribution access

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

The single tag-specific FDA approval precedent recorded a 0% 24-hour move, providing limited basis for a reaction pattern.

Key Terms

companion diagnostic, BRAF V600E/K variants, BRAF/MEK inhibitor combination regimens

3 terms

companion diagnostic regulatory

"approved Labcorp's PGDx elio® tissue complete CDx as a companion diagnostic"

A companion diagnostic is a medical test designed to identify which patients are likely to benefit from a specific drug or medical treatment, much like a key that shows whether a particular lock will open. For investors, these tests matter because they can increase a drug’s chances of approval and market uptake, create a separate revenue stream, and reduce commercial risk by matching treatments to the patients most likely to respond.

BRAF V600E/K variants medical

"carry these BRAF V600E/K variants and may benefit from treatment"

BRAF V600E and V600K variants are specific changes in the BRAF gene that swap one building-block of the protein, producing an always-on signal that drives some cancers to grow. Think of it like a stuck accelerator in a car's growth-control system: cells receive constant 'go' signals. These variants matter to investors because they define patient groups for targeted drugs, affect clinical trial design and approval chances, and shape the market for diagnostics and therapies.

BRAF/MEK inhibitor combination regimens medical

"FDA-approved BRAF inhibitors and BRAF/MEK inhibitor combination regimens"

Combination regimens of BRAF and MEK inhibitors are cancer drug therapies that pair two targeted medicines: one that blocks an abnormal BRAF protein often driving tumor growth and another that blocks the downstream MEK protein in the same signaling pathway. Like closing two linked valves to stop a leak, the two-drug approach can change how well a tumor responds and how long that response lasts, which affects clinical trial results, regulatory approvals, and commercial value for drug developers and investors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Labcorp's FDA‑approved PGDx elio® tissue complete CDx helps identify advanced melanoma patients with certain BRAF variants eligible for BRAF and BRAF/MEK inhibitor therapies
• Supports access to targeted treatment options for the deadliest form of skin cancer

BURLINGTON, N.C., Aug. 10, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced that the U.S. Food and Drug Administration (FDA) has approved Labcorp's PGDx elio® tissue complete CDx as a companion diagnostic to help identify patients with advanced melanoma with certain BRAF variants who may benefit from treatment with FDA-approved targeted therapiesⁱ.

Addressing a Critical Need in Advanced Melanoma
Melanoma is the deadliest form of skin cancer, with a five‑year survival rate of just 16% for patients diagnosed with stage IV disease. However, targeted therapies are an important treatment option for patients with advanced melanoma whose tumors have a BRAF alteration. As a companion diagnostic, PGDx elio tissue complete CDx helps clinicians identify which melanoma patients carry these BRAF V600E/K variants and may benefit from treatment with FDA-approved BRAF inhibitors and BRAF/MEK inhibitor combination regimens.

"Advanced melanoma is an extremely aggressive and life‑threatening cancer, but targeted treatments are offering real hope for patients," said Shakti Ramkissoon, M.D., Ph.D., vice president, medical lead for oncology at Labcorp. "Labcorp's FDA‑approved companion diagnostic improves access to these therapies by allowing clinicians to confirm which patients may be eligible for and can start receiving those treatments as soon as possible."

A Comprehensive and Scalable Testing Solution
Labcorp's PGDx elio tissue complete CDx is approved for use by qualified healthcare professionals across hospitals and clinical laboratories, supporting broader patient access to high-quality molecular testing. As a kit-based solution, the companion diagnostic can be implemented directly within hospitals and health systems, expanding access to testing while enabling organizations to retain samples and data that may inform future clinical research.

The addition of Labcorp's PGDx elio tissue complete CDx reflects the continued expansion of Labcorp's precision medicine portfolio, which includes comprehensive tissue- and liquid-based oncology diagnostics designed to support personalized care. For more information about PGDx elio tissue complete or Labcorp's oncology solutions, visit https://www.labcorp.com/oncology/providers/testing-solutions/kitted-solutions/pgdx-elio-tissue-complete-cdx.

About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.com.

ⁱPGDx elio tissue complete CDx is a qualitative next generation sequencing-based in vitro diagnostic device that uses a high-throughput hybridization-based capture technology utilizing DNA isolated from formalin-fixed paraffin embedded tumor tissue. The PGDx elio tissue complete CDx targeted panel can detect single nucleotide variants, small insertions and deletions, copy number amplifications, and translocations. It is intended to be used as a companion diagnostic to identify melanoma patients who may benefit from treatment with targeted therapies listed below in accordance with the approved therapeutic product labeling.

PGDx elio tissue complete CDx Indications
Indication: Melanoma
Biomarker: BRAF V600E/ BRAF V600K
Therapy: BRAF inhibitors approved by FDA or BRAF/MEK inhibitor combinations approved by FDA

View original content to download multimedia:https://www.prnewswire.com/news-releases/labcorp-announces-fda-approval-of-companion-diagnostic-supporting-patients-with-advanced-melanoma-302846587.html

SOURCE Labcorp

FAQ

What did the FDA approve for Labcorp (LH) in August 2026 related to melanoma?

The FDA approved Labcorp’s PGDx elio tissue complete CDx as a companion diagnostic for advanced melanoma. According to Labcorp, the test helps identify patients with specific BRAF V600E/K variants who may benefit from FDA‑approved BRAF and BRAF/MEK inhibitor therapies.

How does Labcorp’s PGDx elio tissue complete CDx help patients with advanced melanoma (LH)?

The PGDx elio tissue complete CDx identifies advanced melanoma patients whose tumors carry BRAF V600E/K variants. According to Labcorp, this enables clinicians to determine which patients may be eligible for FDA‑approved BRAF inhibitor or BRAF/MEK inhibitor combination treatments, supporting more targeted therapeutic decisions.

Which patients are eligible for Labcorp’s PGDx elio tissue complete CDx testing in advanced melanoma?

The test is intended for patients with advanced melanoma to detect specific BRAF V600E/K variants. According to Labcorp, those patients whose tumors show these variants may be considered for FDA‑approved BRAF inhibitor and BRAF/MEK inhibitor combination regimens as treatment options.

Where can Labcorp’s PGDx elio tissue complete CDx for melanoma be used?

PGDx elio tissue complete CDx is approved for use by qualified healthcare professionals in hospitals and clinical laboratories. According to Labcorp, its kit‑based format allows implementation within hospitals and health systems, supporting broader access to high‑quality molecular testing for advanced melanoma patients.

How does the PGDx elio tissue complete CDx approval affect Labcorp’s precision oncology portfolio (LH)?

The approval adds PGDx elio tissue complete CDx to Labcorp’s existing precision medicine offerings. According to Labcorp, it expands a portfolio that already includes comprehensive tissue‑ and liquid‑based oncology diagnostics designed to support personalized care and targeted treatment decisions for cancer patients.

Why is a BRAF companion diagnostic important for advanced melanoma treatment outcomes?

A BRAF companion diagnostic identifies which advanced melanoma patients have tumors with BRAF alterations like V600E/K. According to Labcorp, this information guides use of FDA‑approved targeted BRAF and BRAF/MEK inhibitor therapies, an important treatment option in a cancer type with low stage IV survival rates.